Organization | Government of the Democratic Republic of the Congo

Government of the Democratic Republic of the Congo Report issue

Government Phase 3 Phase 4

Founded: Kinshasa Congo (2003)

Organization Overview

First Clinical Trial

2008

NCT01772940

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Alternative names

L'Institut National de Recherche Biomédicale RDC | Ministère de la Santé de la RDC | Ministry of Public Health, Democratic Republic of the Congo

Active Ingredients

Drugs in Phase 4 Trials (17)

amodiaquine (camoquin) (2 trials)

artemether (1 trial)

artesunate (2 trials)

coartem (1 trial)

dihydroqinghaosu (1 trial)

eflornithine (ornidyl) (1 trial)

emtricitabine (emtriva) (1 trial)

lamivudine (epivir) (1 trial)

lopinavir (Kaletra) (1 trial)

lumefantrine (Coartem) (2 trials)

nevirapine (viramune) (1 trial)

nifurtimox (1 trial)

piperaquinoline (1 trial)

pyrethrins (rid mousse) (1 trial)

ritonavir (Norvir) (1 trial)

tenofovir (viread) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 3 Trials (3)

ad26.zebov (1 trial)

imvamune (1 trial)

mva-bn-filo (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hemorrhagic Fever, Ebola (Phase 3)

Malaria (Phase 4)

Monkeypox (Phase 3)

Smallpox (Phase 3)

Trypanosomiasis (Phase 4)

Trypanosomiasis, African (Phase 4)

Virus Diseases (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 20